An interventional study of Beetroot Juice and Placebo in HIV/AIDS, sponsored by Universidade Federal do Rio de Janeiro. Completed at 1 site in Brazil. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-29.
Sponsored by Universidade Federal do Rio de Janeiro · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil — 7 open to participants now, 10 under way, 4 of them phase 3. Acquired Immunodeficiency Syndrome · Brazil.
Among the 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil, this one is the 41st largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2017, is one of 11 with no phase, and was the 40th registered.
3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →7 of the 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil are open now. Recruiting first, the newest first:
Federal University of São Paulo · Sites in Brazil
Ages 18–60
Federal University of São Paulo · Sites in Brazil
Ages 18–65
Hospital Alemão Oswaldo Cruz · Sites in Brazil
Ages 18+
Federal University of Health Science of Porto Alegre · Sites in Brazil
Ages 18+
Code Pharma · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 59 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 132 across the 42 interventional studies, 923 across the 14 observational. Of the 40 that completed or were terminated, 16 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 57 have an industry lead sponsor. The 10 most frequent:
Universidade Federal do Rio de Janeiro is the lead sponsor of 123 studies on the registry; 11 are open to participants now.
Universidade Federal do Rio de Janeiro has 1 study filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Acquired Immunodeficiency Syndrome with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07044297Phase 3Merck Sharp & Dohme LLCA Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | 2027-07-22 |
| NCT07118683Hospital Alemão Oswaldo CruzBRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV/AIDS | 2026-11 |
| NCT06805656Federal University of São PauloMulti Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals | 2027-03-01 |
| NCT06497504GlaxoSmithKlineStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | 2027-04-22 |
| NCT07903441Federal University of São PauloMultiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 57 studies in Acquired Immunodeficiency Syndrome with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Administration of antiretroviral therapy has brought benefits for infective human immunodeficiency virus-1 (HIV-1)-patients, reducing the number of AIDS-related morbidity and mortality. However, it is responsible for intensifying complications triggered by the chronic inflammatory state associated with virus infection, such as cardiovascular diseases. The current study evaluated effects of single dose (140mL) of Beetroot Juice (BJ) on macro and microvascular endothelial function in HIV-1-patients undergoing antiretroviral terapy, once BJ was shown to be effective in improving these physiological parameters in uninfected individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Beetroot Juice cotaining on average 9mmol of nitrate per dose
Dietary Supplement: Beetroot Juice
Beetroot juice nitrate depleted
Dietary Supplement: Placebo
140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
140ml of Beetroot Juice (nitrate free)
Skeletal Muscle Oxygenation
Changes in skeletal muscle oxygenation in response to exercise will be evaluated by using a near-infrared spectroscopy device.
Time frame: Baseline and approximately after 150 minutes of beetroot juice consumption
Brachial artery flow-mediated dilatation
The brachial artery flow-mediated dilation will be evaluated by using an ultrasound device.
Time frame: Baseline and approximately after 150 minutes of beetroot juice consumption
Urinary nitrate concentrations
Analysis of nitrate in urine will be performed by using high-performance liquid chromatography system.
Time frame: Baseline and approximately 30, 90, and 150 minutes after beetroot juice consumption
Ran from Oct 2017 to primary completion in Aug 2018, 9 months.
Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 9 months is below that.
Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beet juice
Acquired Immunodeficiency Syndrome →
Universidade Federal do Rio de Janeiro →